Literature DB >> 35900650

Klotho Upregulation via PPARγ Contributes to the Induction of Brain Ischemic Tolerance by Cerebral Ischemic Preconditioning in Rats.

Ling-Yan Zhang1,2, Xi-Yun Liu1, A-Chou Su1, Yu-Yan Hu1,2, Jing-Ge Zhang1,2, Xiao-Hui Xian1,2, Wen-Bin Li1,2, Min Zhang3,4.   

Abstract

Cerebral ischemic preconditioning (CIP)-induced brain ischemic tolerance protects neurons from subsequent lethal ischemic insult. However, the specific mechanisms underlying CIP remain unclear. In the present study, we explored the hypothesis that peroxisome proliferator-activated receptor gamma (PPARγ) participates in the upregulation of Klotho during the induction of brain ischemic tolerance by CIP. First we investigated the expression of Klotho during the brain ischemic tolerance induced by CIP. Lethal ischemia significantly decreased Klotho expression from 6 h to 7 days, while CIP significantly increased Klotho expression from 12 h to 7 days in the hippocampal CA1 region. Inhibition of Klotho expression by its shRNA blocked the neuroprotection induced by CIP. These results indicate that Klotho participates in brain ischemic tolerance by CIP. Furthermore, we tested the role of PPARγ in regulating Klotho expression after CIP. CIP caused PPARγ protein translocation to the nucleus in neurons in the CA1 region of the hippocampus. Pretreatment with GW9962, a PPARγ inhibitor, significantly attenuated the upregulation of Klotho protein and blocked the brain ischemic tolerance induced by CIP. Taken together, it can be concluded that Klotho upregulation via PPARγ contributes to the induction of brain ischemic tolerance by CIP.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Brain ischemic tolerance; Cerebral ischemic preconditioning; Hippocampus; Klotho; PPARγ

Year:  2022        PMID: 35900650     DOI: 10.1007/s10571-022-01255-y

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   4.231


  39 in total

1.  Decreased concentration of Klotho in the cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis.

Authors:  Mohammad Sajad Emami Aleagha; Bahaadin Siroos; Mona Ahmadi; Mohammad Balood; Alireza Palangi; Afsaneh Nazari Haghighi; Mohammad Hossein Harirchian
Journal:  J Neuroimmunol       Date:  2015-02-21       Impact factor: 3.478

2.  CD200R1 and CD200 expression are regulated by PPAR-γ in activated glial cells.

Authors:  Guido Dentesano; Joan Serratosa; Josep M Tusell; Pol Ramón; Tony Valente; Josep Saura; Carme Solà
Journal:  Glia       Date:  2014-03-17       Impact factor: 7.452

3.  PPAR-γ agonist GL516 reduces oxidative stress and apoptosis occurrence in a rat astrocyte cell line.

Authors:  Letizia Giampietro; Marialucia Gallorini; Barbara De Filippis; Rosa Amoroso; Amelia Cataldi; Viviana di Giacomo
Journal:  Neurochem Int       Date:  2019-04-01       Impact factor: 3.921

4.  Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho.

Authors:  Reeti Behera; Amanpreet Kaur; Marie R Webster; Suyeon Kim; Abibatou Ndoye; Curtis H Kugel; Gretchen M Alicea; Joshua Wang; Kanad Ghosh; Phil Cheng; Sofia Lisanti; Katie Marchbank; Vanessa Dang; Mitchell Levesque; Reinhard Dummer; Xiaowei Xu; Meenhard Herlyn; Andrew E Aplin; Alexander Roesch; Cecilia Caino; Dario C Altieri; Ashani T Weeraratna
Journal:  Clin Cancer Res       Date:  2017-02-23       Impact factor: 12.531

5.  Temporal profile of the effects of pretreatment with brief cerebral ischemia on the neuronal damage following secondary ischemic insult in the gerbil: cumulative damage and protective effects.

Authors:  H Kato; Y Liu; T Araki; K Kogure
Journal:  Brain Res       Date:  1991-07-12       Impact factor: 3.252

6.  Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.

Authors:  Jing Jin; Jennifer Albertz; Zhihong Guo; Qi Peng; Gay Rudow; Juan C Troncoso; Christopher A Ross; Wenzhen Duan
Journal:  J Neurochem       Date:  2013-03-05       Impact factor: 5.372

7.  Proteomic differences in brain vessels of Alzheimer's disease mice: Normalization by PPARγ agonist pioglitazone.

Authors:  AmanPreet Badhwar; Rebecca Brown; Danica B Stanimirovic; Arsalan S Haqqani; Edith Hamel
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-20       Impact factor: 6.200

8.  The antiaging protein Klotho enhances oligodendrocyte maturation and myelination of the CNS.

Authors:  Ci-Di Chen; Jacob A Sloane; Hu Li; Nurgul Aytan; Eustathia L Giannaris; Ella Zeldich; Jason D Hinman; Alpaslan Dedeoglu; Douglas L Rosene; Rashmi Bansal; Jennifer I Luebke; Makoto Kuro-o; Carmela R Abraham
Journal:  J Neurosci       Date:  2013-01-30       Impact factor: 6.167

9.  Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease.

Authors:  Pablo Garrido-Gil; Belen Joglar; Ana I Rodriguez-Perez; Maria J Guerra; Jose L Labandeira-Garcia
Journal:  J Neuroinflammation       Date:  2012-02-22       Impact factor: 8.322

10.  Molecular Regulatory Mechanism and Toxicology of Neurodegenerative Processes in MPTP/Probenecid-Induced Progressive Parkinson's Disease Mice Model Revealed by Transcriptome.

Authors:  Weiwei Yang; Wenwen Hao; Zhuo Meng; Shiyan Ding; Xiaodi Li; Tao Zhang; Weixiao Huang; Lian Xu; Yu Zhang; Jian Yang; Xiaosong Gu
Journal:  Mol Neurobiol       Date:  2020-09-30       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.